News
Merck, Pfizer get EU nod for Bavencio as bladder cancer main...
Pfizer and partner Merck KGaA now have approval on both sides of the Atlantic for their checkpoint inhibitor Bavencio as a first-line maintenance therapy for bladder cancer, stealing a marc
